OVERRVIEW
Acne vulgaris is a common disease in adolescents with a reported prevalence of 70-87%. This disease state is a cause for concern due to the psychosocial impact among patients especially adolescents. There are multiple drug combinations with different mechanisms to treat acne vulgaris, but this depends on the severity of acne: mild, moderate, or severe. This review will examine the treatment guidelines of acne vulgaris and the currently available acne drug products and their coverage criteria.

Table 1: Available Acne Agents (Current as of 12/2018)

<table>
<thead>
<tr>
<th>Therapeutic Class</th>
<th>Generic Name (Brand Name)</th>
<th>Available Strengths</th>
<th>Formulary Limits</th>
<th>Average Cost per 30 days</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topical Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzoyl Peroxide</td>
<td>Bar, Cleanser, Cream, Gel, Lotion, Wash</td>
<td>5%, 10%</td>
<td>--</td>
<td>$6.90</td>
<td></td>
</tr>
<tr>
<td>Sulfacetamide/Sulfur Cleanser</td>
<td>-</td>
<td>FL</td>
<td>$145.89</td>
<td>Limit 1 fill per month.</td>
<td></td>
</tr>
<tr>
<td>Clindamycin Phosphate Gel, Lotion, Solution</td>
<td>1%</td>
<td>--</td>
<td>$53.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin Base/Ethanol Gel, Solution, Swab</td>
<td>2%</td>
<td>--</td>
<td>$70.81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tretinoin Cream, Gel</td>
<td>0.01%, 0.025%, 0.05%, 0.1%</td>
<td>AL</td>
<td>$116.90</td>
<td>Restricted to use by patients &lt;35yo. Tretinoin 0.05% Gel is non-formulary.</td>
<td></td>
</tr>
<tr>
<td>Adapalene Cream, Gel, Lotion</td>
<td>0.1%, 0.3%</td>
<td>AL</td>
<td>$169.99</td>
<td>Restricted to use by patients &lt;35yo. Differin 0.1% Gel (OTC) is formulary.</td>
<td></td>
</tr>
<tr>
<td>Tazarotene (Tazorac) Cream, Gel</td>
<td>0.05%, 0.1%</td>
<td>PA; QL</td>
<td>$308.88</td>
<td>Reserved for treatment failure to Tretinoin + BPO AND Adapalene + BPO. Limit 30gm per month.</td>
<td></td>
</tr>
<tr>
<td>Dapsone (Aczone) Gel</td>
<td>5%</td>
<td>PA; QL</td>
<td>$393.63</td>
<td>Reserved for treatment failure to Tretinoin/Adapalene + Clindamycin/Erythromycin + BPO. Limit 30gm per month.</td>
<td></td>
</tr>
<tr>
<td>Combination Agents</td>
<td>All combination acne products (BenzaClin, Benzamycin, Epiduo, etc)</td>
<td>NF</td>
<td>-</td>
<td>Use agents separately.</td>
<td></td>
</tr>
</tbody>
</table>
**Coverage Policy**

- **Oral Retinoids**
  - **Isotretinoin (Claravis, Amnesteem, Myorisan, Zenatane)**
    - 10mg, 20mg, 40mg
    - PA
    - $642.89
    - Reserved for treatment failure to 2 conventional treatments: BPO, topical retinoids, topical/oral antibiotics. Approved up to 6 months at a time.
  - **Isotretinoin (Absorica)**
    - 10mg, 20mg, 40mg
    - NF
    - -

**AL = Age Limit; NF = Non-Formulary; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy**

---

**EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION**

Below are the coverage criteria and required information for each agent. These coverage criteria have been reviewed approved by the HPSJ Pharmacy & Therapeutics (P&T) Advisory Committee. For conditions not covered under this Coverage Policy, HPSJ will make the determination based on Medical Necessity as described in HPSJ Medical Review Guidelines (UM06).

**Topical Retinoids**

**Tretinoin (Retin-A); Adapalene (Differin)**

- **Coverage Criteria:** Tretinoin and Adapalene are restricted to patients under the age of 35 OR for patients 35 and older who have a diagnosis of moderate acne as evidenced by documentation of clinical evaluation by provider with treatment failure to topical Clindamycin/Erythromycin with Benzoyl Peroxide OR prescribed by a dermatologist.
- **Limits:** None
- **Required Information for Approval:** (Non-dermatologist prescribers) Clinic notes documenting diagnosis of moderate-severe acne with treatment failure to topical antibiotics and benzoyl peroxide; prescription history of topical/systemic antibiotics and benzoyl peroxide.
- **Other Notes:** Adapalene 0.1% Gel (OTC) is formulary preferred.
- **Non-Formulary:**
  - Retin-A Micro (tretinoin microspheres)
  - Renova (tretinoin – wrinkles)
  - Adapalene 0.1% Gel (Rx version)
  - Tretinoin 0.05% Gel

**Tazarotene**

**Tazarotene (Tazorac)**

- **Coverage Criteria:** Tazarotene is reserved for use by Dermatologists or for patients with documented treatment failure/intolerance to Tretinoin AND Adapalene in combination with Benzoyl Peroxide.
- **Limits:** 30gm per month.
- **Required Information for Approval:** Prescription history of Tretinoin, Adapalene, and Benzoyl Peroxide.
- **Other Notes:** None

**Oral Retinoids**

**Isotretinoin (Amnesteem, Claravis, Myorisan, Zenatane)**

- **Coverage Criteria:** Isotretinoin is step therapy to failing 2 of the following conventional acne agents: benzoyl peroxide, topical retinoids, topical antibiotics, OR oral antibiotics.
- **Limits:** Approval for 6 months at a time; renewal required after 6 months.
- **Required Information for Approval:** Prescription history of previous antibiotics, topical retinoids/antibiotics, or benzoyl peroxide.
- **Non-Formulary: Absorica**
## Oral Antibiotics

*Doxycycline Monohydrate, Minocycline, Tetracycline*, Erythromycin, Azithromycin, Clindamycin, Trimethoprim, Amoxicillin*

- **Coverage Criteria:** None
- **Limits:** None
- **Required Information for Approval:** N/A
- **Non-Formulary:**
  - Tetracycline is non-formulary.
  - Doxycycline Hyclate is non-formulary.

## Topical Antibiotics

*Clindamycin, Erythromycin*

- **Coverage Criteria:** None
- **Limits:** None
- **Required Information for Approval:** N/A

*Dapsone (Aczone)*

- **Coverage Criteria:** Dapsone is reserved for patients with documented treatment failure/intolerance to Tretinoin/Adapalene AND topical Clindamycin/Erythromycin AND Benzoyl Peroxide.
- **Limits:** 30gm per month.

## OTC & Other Products

*Benzoyl Peroxide 5%, 10%; Salicylic Acid, Sulfacetamide-Sulfur*  

- **Coverage Criteria:** None
- **Limits:** Sulfacetamide-Sulfur products are limited to 1 fill per month.
- **Required Information for Approval:** N/A
- **Non-Formulary:**
  - Benzoyl Peroxide 4%, 6% formulations are non-formulary.

### CLINICAL JUSTIFICATION

The effectiveness of topical antibiotics, retinoids, and benzoyl peroxide for acne treatment has been well established. For mild acne, the 2016 *Journal of American Academy of Dermatology* and 2013 *Pediatrics Journal* recommend over-the-counter products (benzoyl peroxide, salicylic acid, sulfur agents) as first-line agents with or without topical antibiotics or retinoids. Moderate acne usually requires a combination of topical therapies (topical antibiotics, topical retinoids, and over-the-counter agents). Tazarotene is clinically comparable to topical tretinoin and adapalene with adapalene being more tolerable than tretinoin. Long-term use of oral tetracyclines antibiotics (minocycline and doxycycline) may be useful for prevention of acne flares. Monotherapy with oral antibiotics has a similar efficacy to benzoyl peroxide in combination with topical antibiotics. Severe acne or cystic acne requires 5 to 6 months of systemic treatment with oral retinoids, often used in combination with topical therapies. For patients’ with hormonal-induced acne, oral contraceptives may be used as adjunctive/monotherapies therapies. While only 3 contraceptives have a labeled indication for acne management, all oral contraceptives may be used for acne treatment. Topical combination products, while formulated for convenience, are significantly less cost-effective. Consequently, combination products are non-formulary.
REFERENCES

REVIEW & EDIT HISTORY

<table>
<thead>
<tr>
<th>Document Changes</th>
<th>Reference</th>
<th>Date</th>
<th>P&amp;T Chairman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creation of Policy</td>
<td>Contraceptives May09_JHP01 5-11-09.doc</td>
<td>5/2009</td>
<td>Allen Shek, PharmD</td>
</tr>
<tr>
<td>Updated Policy</td>
<td>OC Class Review 9-20-11.doc</td>
<td>9/2011</td>
<td>Allen Shek, PharmD</td>
</tr>
<tr>
<td>Updated Policy</td>
<td>Formulary Realignment PT 9-18-12.xls</td>
<td>9/2012</td>
<td>Allen Shek, PharmD</td>
</tr>
<tr>
<td>Updated Policy</td>
<td>Acne Class Review.docx</td>
<td>5/2015</td>
<td>Jonathan Szkotak, PharmD</td>
</tr>
<tr>
<td>Updated Policy</td>
<td>HPSJ Coverage Policy – Dermatology – Acne 2015-5.docx</td>
<td>5/2015</td>
<td>Johnathan Yeh, PharmD</td>
</tr>
<tr>
<td>Updated Policy</td>
<td>HPSJ Coverage Policy – Dermatology – Acne 2017-5.docx</td>
<td>5/2017</td>
<td>Johnathan Yeh, PharmD</td>
</tr>
</tbody>
</table>

Note: All changes are approved by the HPSJ P&T Committee before incorporation into the utilization policy.